2026-04-02 19:32:15
BioCorRx Inc. Enters Stock Exchange Agreement to Acquire Majority Stake in Subsidiary
Expected Stock impact: Slightly Positive
On April 2, 2026, BioCorRx Inc. filed an 8-K report detailing a significant stock exchange agreement executed on March 26, 2026. The agreement involves the transfer of 1,215 shares of common stock of BioCorRx Pharmaceuticals, Inc., a majority-owned subsidiary of BioCorRx, from key shareholders to the company. In exchange, the shareholders will receive a total of 2,263,371 shares of BioCorRx's common stock. This transaction is part of the company's broader Plan of Reorganization, which aims to consolidate control over its subsidiary under Section 368(c) of the Internal Revenue Code, qualifying the exchange as a tax-free reorganization under Section 368(a)(1)(B). The agreement was approved by the Board of Directors in accordance with the company's related party transaction policy. The transaction is expected to enhance BioCorRx's operational execution and strategic outlook by solidifying its ownership structure and potentially improving its financial position. The Parent Shares issued will be the sole consideration for the shareholders, with no cash or other property exchanged. This move is anticipated to have a small positive effect on the stock price as it reflects a strategic consolidation of assets and control within the company.
